Kidney Stone Model

Creative Bioarray has successfully developed a wide range of experimental models for kidney diseases. One such model we offer is designed to simulate human kidney stones. We take great pride in providing thoroughly validated and dependable models for testing compounds. This ensures that any data obtained from these models is not only biologically pertinent, but also holds clinical significance. Our unwavering dedication to excellence guarantees the dependability and relevance of the data for your research requirements.

Kidney stones, which affect around 8% of the population, are primarily composed of calcium oxalate (80%), with the rest being uric acid, struvite, and other rarer types. Despite advancements in treatments such as ureteroscopy, shock wave lithotripsy, and percutaneous nephrolithotomy, recurrence rates remain high, and pharmacological options such as citrate and thiazide diuretics have limitations. To address this, various in vitro and in vivo urolithiasis models have been developed to study the pathogenesis of calcium oxalate stones and to test new therapies. Our kidney stone model is designed to facilitate a deeper understanding of stone formation and to accelerate the development of more effective treatments. We welcome your inquiry to discover how our model can support your research and contribute to advancements in urology.

Our Kidney Stone Model

  • Available Animal

Rat

  • Modeling Method

Following the acclimation period, rats in the model group receive ethylene glycol via their drinking water and are administered ammonium chloride solution intragastrically daily for a duration of six weeks.

  • Endpoints
  • Clinical observation of kidney
  • Serum analysis: urea, uric acid, creatinine, calcium, and phosphorus
  • Micro CT of kidney
  • Histology analysis
  • qPCR or Western Blot
  • Other customized endpoints

Example Data

Upregulation of CREB1 significantly reduces kidney crystal deposition in KSD rats, as shown by Von Kossa staining and decreased renal calcium levels.Fig. 1 Upregulation of CREB1 reduced crystals deposition in the kidney of KSD rats. (A) Von Kossa staining for detecting crystals deposition in renal tissue of the rats. (B) The level of calcium in renal tissue of the rats. (Yu et al. 2021)

Quotation and Ordering

At Creative Bioarray, our team of seasoned scientists is ready to collaborate with you to choose the most appropriate in vivo model for your research needs. We also provide assistance with study design, implementation, and data analysis to ensure the success of your project. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly.

References

  1. Khan, A. In vitro and in vivo models for the study of urolithiasis. Urologia Journal. 2018;85(4):145-149.
  2. Yu, L., et al. CREB1 protects against the renal injury in a rat model of kidney stone disease and calcium oxalate monohydrate crystals-induced injury in NRK-52E cells. Toxicology and Applied Pharmacology, 2021, 413: 115394.

For research use only. Not for any other purpose.